Deerfield Management Company, L.P. (Series C) Keros Therapeutics, Inc. Transaction History

Deerfield Management Company, L.P. (Series C)

$4.76 Billion
Q2 2024

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q3 2020 Nov 16, 2020	SELL	$27.04 - $62.21 $8.11 Million - $18.7 Million	-300,000 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$20.08 - $40.39 $6.02 Million - $12.1 Million	300,000 New	300,000 $11.3 Million

Others Institutions Holding KROS

# of Institutions

157

Shares Held

27.1M

Call Options Held

28.7K

Put Options Held

1.8K

Black Rock Inc. New York, NY

2.51M
Shares

$142 Million
0.0% of portfolio
Vanguard Group Inc Valley Forge, PA

1.76M
Shares

$99.2 Million
0.0% of portfolio
Alkeon Capital Management LLC New York, NY

1.6M
Shares

$90.3 Million
0.12% of portfolio
Darwin Global Management, Ltd. St. Helier, Y9

1.53M
Shares

$86.1 Million
8.43% of portfolio
Orbimed Advisors LLC San Diego, CA

1.27M
Shares

$71.6 Million
1.4% of portfolio

View Full List

About Keros Therapeutics, Inc.

Ticker KROS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,757,000
Market Cap $1.45B
Description
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed ...

More about KROS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Deerfield Management Company, L.P. (Series C), based on Form 13F filings with the SEC.

News

Stay updated on Deerfield Management Company, L.P. (Series C) with notifications on news.

Account